During the COVID-19 outbreak, California Correctional Healthcare Service and California Hospital Association collaborated to redirect doses of monoclonal antibody to correctional facilities to treat high-risk patients who had contracted COVID-19. Providers found a decrease in severity of disease, hospitalization, and death. Learn when treatment with monoclonal antibody is indicated for COVID-19, and how to identify appropriate patients, obtain informed consent, safely infuse, and monitor this high-risk population.
Identify eligible high-risk patients with COVID-19 who would benefit from IV monoclonal antibodies
Demonstrate understanding of the consent, treatment, and monitoring requirements for the use of monoclonal antibodies
Analyze the essential interdisciplinary processes needed to support the use of IV monoclonal antibody treatment in corrections
Michele DiTomas MD, CCHP, California Department of Corrections and Rehabilitation
Eve Hood-Medland MD, California Correctional Healthcare Facility